Enhancing the in vitro cytotoxic activity of Δ⁹-tetrahydrocannabinol in leukemic cells through a combinatorial approach

References

• Guzman M. Cannabinoids: potential anticancer agents. Nat Rev Cancer 2003; 3: 745–755
   PubMed Web of Science ®Google Scholar
• Hall W, Christie M, Currow D. Cannabinoids and cancer: causation, remediation, and palliation. Lancet Oncol 2005; 6: 35–42
   PubMed Web of Science ®Google Scholar
• Jones S, Howl J. Cannabinoid receptor systems: therapeutic targets for tumour intervention. Expert Opin Ther Targets 2003; 7: 749–758
   PubMed Web of Science ®Google Scholar
• Kogan N M. Cannabinoids and cancer. Mini Rev Med Chem 2005; 5: 941–952
   PubMed Web of Science ®Google Scholar
• Liu W M, Powles T B. Cannabinoids: Do they have a role in cancer therapy?. Lett Drug Des Disc 2006; 3: 76–82
   Web of Science ®Google Scholar
• Curran N M, Griffin B D, O'Toole D, Brady K J, Fitzgerald S N, Moynagh P N. The synthetic cannabinoid R(+)WIN 55,212-2 inhibits the interleukin-1 signaling pathway in human astrocytes in a cannabinoid receptor-independent manner. J Biol Chem 2005; 280: 35797–35806
   PubMed Web of Science ®Google Scholar
• Flygare J, Gustafsson K, Kimby E, Christensson B, Sander B. Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma. FEBS Lett 2005; 579: 6885–6889
   PubMed Web of Science ®Google Scholar
• Lombard C, Nagarkatti M, Nagarkatti P S. Targeting cannabinoid receptors to treat leukemia: role of cross-talk between extrinsic and intrinsic pathways in Δ9-tetrahydrocannabinol (THC)-induced apoptosis of Jurkat cells. Leuk Res 2005; 29: 915–922
   PubMed Web of Science ®Google Scholar
• Sarfaraz S, Afaq F, Adhami V M, Mukhtar H. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res 2005; 65: 1635–1641
   PubMed Web of Science ®Google Scholar
• Powles T, te Poele R, Shamash J, Chaplin T, Propper D, Joel S, Oliver R T, et al. Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway. Blood 2005; 105: 1214–1221
   PubMed Web of Science ®Google Scholar
• Caffarel M M, Sarrio D, Palacios J, Guzman M, Sanchez C. Δ9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res 2006; 66: 6615–6621
   PubMed Web of Science ®Google Scholar
• Carracedo A, Gironella M, Lorente M, Garcia S, Guzman M, Velasco G, et al. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res 2006; 66: 6748–6655
   PubMed Web of Science ®Google Scholar
• Fogli S, Nieri P, Chicca A, Adinolfi B, Mariotti V, Iacopetti P, et al. Cannabinoid derivatives induce cell death in pancreatic MIA PaCa-2 cells via a receptor-independent mechanism. FEBS Lett 2006; 580: 1733–1739
   PubMed Web of Science ®Google Scholar
• Sarnataro D, Pisanti S, Santoro A, Gazzerro P, Malfitano A M, Laezza C, et al. The Cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism. Mol Pharmacol 2006; 70: 1298–1306
   PubMed Web of Science ®Google Scholar
• Greenhough A, Patsos H A, Williams A C, Paraskeva C. The cannabinoid Δ(9)-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells. Int J Cancer 2007; 121: 2172–2180
   PubMed Web of Science ®Google Scholar
• Galve-Roperh I, Sanchez C, Cortes M L, del Pulga T G, Izquierdo M, Guzman M. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 2000; 6: 313–319
   PubMed Web of Science ®Google Scholar
• Sanchez C, de Ceballos M L, del Pulgar T G, Rueda D, Corbacho C, Velasco G, et al. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res 2001; 61: 5784–5789
   PubMed Web of Science ®Google Scholar
• Bouaboula M, Poinot-Chazel C, Bourrie B, Canat X, Calandra B, Rinaldi-Carmona M, et al. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J 1995; 312: 637–647
   PubMed Web of Science ®Google Scholar
• Rueda D, Galve-Roperh I, Haro A, Guzman M. The CB(1) cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase. Mol Pharmacol 2000; 58: 814–820
   PubMed Web of Science ®Google Scholar
• Gomez del Pulgar T, Velasco G, Guzman M. The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem J 2000; 347: 369–373
   PubMed Web of Science ®Google Scholar
• Blazquez C, Casanova M L, Planas A, Del Pulgar T G, Villanueva C, Fernandez-Acenero M J, et al. Inhibition of tumor angiogenesis by cannabinoids. FASEB J 2003; 17: 529–531
   PubMed Web of Science ®Google Scholar
• Casanova M L, Blazquez C, Martinez-Palacio J, Villanueva C, Fernandez-Acenero M J, Huffman J W, et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 2003; 111: 43–50
   PubMed Web of Science ®Google Scholar
• Blazquez C, Gonzalez-Feria L, Alvarez L, Haro A, Casanova M L, Guzman M. Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res 2004; 64: 5617–5623
   PubMed Web of Science ®Google Scholar
• Vaccani A, Massi P, Colombo A, Rubino T, Parolaro D. Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br J Pharmacol 2005; 144: 1032–1036
   PubMed Web of Science ®Google Scholar
• Slamon D J, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783–792
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337–345
   PubMed Web of Science ®Google Scholar
• Sain N, Krishnan B, Ormerod M G, De Rienzo A, Liu W M, Kaye S B, et al. Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT. Mol Cancer Ther 2006; 5: 1197–1208
   PubMed Web of Science ®Google Scholar
• Kurokawa H, Lenferink A E, Simpson J F, Pisacane P I, Sliwkowski M X, Forbes J T, et al. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 2000; 60: 5887–5894
   PubMed Web of Science ®Google Scholar
• Mackeigan J P, Collins T S, Ting J PY. MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem 2000; 275: 38953–38956
   PubMed Web of Science ®Google Scholar
• McDaid H M, Horwitz S B. selective potentiation of paclitaxel (Taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines. Mol Pharm 2001; 60: 290–301
   PubMed Web of Science ®Google Scholar
• Stadheim T A, Xiao H, Eastman A. Inhibition of extracellular signal-regulated kinase (ERK) mediates cell cycle phase independent apoptosis in vinblastine-treated ML-1 Cells. Cancer Res 2001; 61: 1533–1540
   PubMed Web of Science ®Google Scholar
• Wu J, Wong W L, Khosravi F, Minden M D, Penn L Z. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res 2004; 64: 6461–6468
   PubMed Web of Science ®Google Scholar
• Ozaki K, Kishikawa F, Kohno M. Blockade of the ERK pathway markedly sensitises tumor cells to HDAC inhibitor-induced death. Biochem Biophys Res Commun 2006; 339: 1171–1177
   PubMed Web of Science ®Google Scholar
• Jacobsson S O, Rongard E, Stridh M, Tiger G, Fowler C J. Serum-dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability. Biochem Pharmacol 2000; 60: 1807–1813
   PubMed Web of Science ®Google Scholar
• Chou T C, Talalay P. Quantitative analysis of dose–effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27–55
   PubMedGoogle Scholar
• Liu W M, Stimson L A, Joel S P. The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive CML cells: synergistic interactions with anti-leukaemic agents. Brit J Cancer 2002; 86: 1472–1478
   PubMed Web of Science ®Google Scholar
• Liu W M, Scott K A, Shahin S, Propper D J. The in vitro effects of CRE-decoy oligonucleotides in combination with conventional chemotherapy in colorectal cancer cell lines. Eur J Biochem 2004; 271: 2773–2781
   PubMedGoogle Scholar
• Laemmli U K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680–685
   PubMed Web of Science ®Google Scholar
• Liu W M, Powles T B, Shamash J, Propper D J, Oliver R TD, Joel S P. The effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity. Oncogene 2004; 23: 981–990
   PubMed Web of Science ®Google Scholar
• Chou T C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58: 621–681
   PubMed Web of Science ®Google Scholar
• Liu W M. Enhancing the cytotoxic activity of novel targeted therapies–is there a role for a combinatorial approach?. Curr Clin Pharmacol 2008; 3: 108–117
   PubMedGoogle Scholar
• Ripple M O, Kalmadi S, Eastman A. Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival. Breast Cancer Res Treat 2005; 93: 177–188
   PubMed Web of Science ®Google Scholar
• O'Gorman D M, McKenna S L, McGahon A J, Knox K A, Cotter T G. Sensitisation of HL60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of PI3-kinase survival signals. Leukemia 2000; 14: 602–611
   PubMed Web of Science ®Google Scholar
• Milella M, Kornblau S M, Estrov Z, Carter B Z, Lapillonne H, Harris D, et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest 2001; 108: 851–859
   PubMed Web of Science ®Google Scholar
• Kohno M, Pouyssegur J. Targeting the ERK signaling pathway in cancer therapy. Ann Med 2006; 38: 200–211
   PubMed Web of Science ®Google Scholar
• DeFeo-Jones D, Barnett S F, Fu S, Hancock P J, Haskell K M, Leander K R, et al. Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol Cancer Ther 2005; 4: 271–279
   PubMed Web of Science ®Google Scholar
• Pavlopoulos S, Thakur G A, Nikas S P, Makriyannis A. Cannabinoid receptors as therapeutic targets. Curr Pharm Des 2006; 12: 1751–1769
   PubMed Web of Science ®Google Scholar
• Herkenham M, Lynn A B, Little M D, Johnson M R, Melvin L S, de Costa B R, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci 1990; 87: 1932–1936
   PubMed Web of Science ®Google Scholar
• Piomelli D, Beltramo M, Giuffrida A, Stella N. Endogenous cannabinoid signaling. Neurobiol Dis 1998; 5: 462–473
   PubMed Web of Science ®Google Scholar
• Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995; 232: 54–61
   PubMedGoogle Scholar
• McKallip R J, Lombard C, Fisher M, Martin B R, Ryu S, Grant S, et al. Targetting CB2 cannabinoid receptors as novel therapy to treat malignant lymphoblastic disease. Blood 2002; 100: 627–634
   PubMed Web of Science ®Google Scholar
• Guzman M, Galve-Roperh I, Sanchez C. Ceramide: a new second messenger of cannabinoid action. Trends Pharmacol Sci 2001; 22: 19–22
   PubMed Web of Science ®Google Scholar
• Velasco G, Galve-Roperh I, Sanchez C, Blazquez C, Haro A, Guzman M. Cannabinoids and ceramide: two lipids acting hand-by-hand. Life Sci 2005; 77: 1723–1731
   PubMed Web of Science ®Google Scholar
• Jia W, Hegde V L, Singh N P, Sisco D, Grant S, Nagarkatti M, et al. Δ9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of bad to mitochondria. Mol Cancer Res 2006; 4: 549–562
   PubMed Web of Science ®Google Scholar